孤独症谱系障碍临床前模型中药物与微生物群疗法的疗效:系统综述
该研究系统综述了2010至2025年间52项在经典孤独症谱系障碍(ASD)动物模型中评估药物与微生物群靶向干预的研究,干预涵盖催产素能药物、兴奋/抑制(E/I)平衡靶点、代谢药物、大麻素类、嘌呤类及益生菌、益生元、粪菌移植等。综述显示ASD样行为缺陷可通过作用于神经递质、神经炎症、代谢和肠脑轴的多种干预调节,支持ASD病理生理的多因素网络本质。
要点
- ASD样行为缺陷可在临床前模型中被多类系统干预调节。
- 干预涉及神经递质、神经炎症、代谢与肠脑轴等多条通路。
- ASD病理生理可能为多系统交互网络而非单一分子缺陷。
核心结论
- ASD样行为缺陷在临床前模型中可通过靶向神经递质、神经炎症、代谢和肠脑轴等不同生物系统的干预加以调节。
- ASD病理生理具有多因素性质,源于相互作用的系统性过程网络而非单一分子缺陷。
研究设计与样本
- 系统综述,纳入2010至2025年间的52项近期研究,研究对象为经典ASD动物模型。
- 干预按治疗类别分组,包括催产素能药物、E/I平衡治疗靶点、代谢药物、大麻素类、嘌呤类干预及新兴靶点,以及益生菌、益生元和粪菌移植等微生物群导向策略。
主要发现
- 综述整合了各模型中的效应方向与稳健性,识别出多数潜在候选药物并评估了新策略的疗效。
- 综述识别了关键转化差距,并指出方法学差异、结局指标变异、报告不完整和生物学混杂因素等问题。
- 纳入研究报告了药物或微生物群干预后ASD关键行为学结局。
临床怎么用
- 临床前证据提示ASD干预可能需要面向多系统的综合策略,而非仅针对单一分子靶点。
- 将动物模型疗效向人类临床转化时需考虑方法学标准化与结局指标一致性问题。
局限性
- 纳入研究存在方法学差异、结局指标变异、报告不完整和生物学混杂因素。
- 研究结果存在过度概括风险,限制了创新药物的评估与向人类临床相关性的转化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autism spectrum disorder (ASD) is a multifactorial neurodevelopmental condition in which pharmacological and microbiota-targeted interventions are emerging as promising therapeutic avenues. Animal models are the main tool to investigate etiology, molecular mechanisms and screening for pharmacological therapies. Methodological differences, outcome measure variability, incomplete reporting, biological confounders, and overgeneralization of the results made evaluating innovative pharmacological agents challenging. These limitations in the field highlight a need for systematic and standardized research to reliably assess and translate pharmacological interventions from ASD animal models to human clinical relevance. SUBJECTS: This systematic review synthesized efficacy evidence for pharmacological and microbiota-based therapies across established ASD animal models. RESULTS: We identified 52 recent (2010-2025) studies that reported key ASD behavioral outcomes after pharmacological or microbiota-focused treatments. Interventions were grouped into therapeutic classes - including oxytocinergic agents, E/I balance therapeutic targets, metabolic drugs, cannabinoids, purine-based interventions and emerging targets - alongside microbiota-directed strategies such as probiotics, prebiotics, and fecal microbiota transplantation. By integrating effect directions and robustness across models, we identified most potential drug candidates, evaluated the efficacy of novel strategies, and recognized critical translational gaps. The reviewed studies demonstrate that ASD-like behavioral deficits in preclinical models can be modulated through interventions targeting diverse biological systems, including neurotransmission, neuroinflammation, metabolism, and the gut-brain axis. CONCLUSIONS: These findings support the multifactorial nature of ASD pathophysiology which arises from a network of interacting systemic processes rather than a single molecular defect. It could explain the limited success of traditionally narrowly targeted interventions and suggest a paradigm shift into a more systemic approach.
引用
- Kunevičius A, Gawlińska K, Burokas A, et al. Efficacy of pharmacological and microbiota-based therapies in preclinical models of autism spectrum disorder: a systematic review. Mol Psychiatry. 2026. PMID: 42243298. doi:10.1038/s41380-026-03663-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。